Evidence map›Paper›PMID 37357528›Full record

ArticleActa biochimica et biophysica Sinica2023

Crystal structures of main proteases of SARS-CoV-2 variants bound to a benzothiazole-based inhibitor.

Jiqing Luo, Weiwei Wang, Haihai Jiang, Wenwen Li, Pei Zeng, Jie Wang, Xuelan Zhou, Xiaofang Zou, Shenghui Chen, Qisheng Wang and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Jiqing LuoCollege of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, China.
Weiwei WangShanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai 201204, China.
Haihai JiangSchool of Basic Medical Sciences, Nanchang University, Nanchang 330031, China.
Wenwen LiShenzhen Crystalo Biopharmaceutical Co., Ltd., Shenzhen 518118, China.
Pei ZengJiangxi Jmerry Biopharmaceutical Co., Ltd., Ganzhou 341000, China.
Jie WangJiangxi Jmerry Biopharmaceutical Co., Ltd., Ganzhou 341000, China.
Xuelan ZhouJiangxi Jmerry Biopharmaceutical Co., Ltd., Ganzhou 341000, China.
Xiaofang ZouJiangxi Jmerry Biopharmaceutical Co., Ltd., Ganzhou 341000, China.
Shenghui ChenNanchang Reproductive Hospital, Nanchang 330000, China.
Qisheng WangShanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai 201204, China.
Jin ZhangSchool of Basic Medical Sciences, Nanchang University, Nanchang 330031, China.
Jian LiCollege of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, China.
Chinese Academy of Sciences · CNGannan Medical University · CNNanchang University · CNThird Hospital of Nanchang · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Main protease (M

Indexed as

COVID-19SARS-CoV-2Antiviral AgentsBenzothiazolesCysteine EndopeptidasesHumansMolecular Docking SimulationProtease InhibitorsAntiviral AgentsBenzothiazolesCysteine EndopeptidasesProtease Inhibitorsbenzothiazoleinhibitormain proteaseSARS-CoV-2variantYH-53

Identifiers

PMID37357528
PMCPMC10448042
OpenAlexW4353101218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.